Skip to main content

Advertisement

SpringerLink
Log in

Extensive stage small cell lung cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Small cell lung cancer is a rapidly proliferating, biologically aggressive form of lung cancer that has a short survival without treatment. Chemotherapy is the foundation of the therapeutic approach to patients with small cell lung cancer. Most patients present with extensive disease, and, although few patients are cured, significant improvement in survival is possible with modern chemotherapy. The role of radiation therapy in extensive disease is palliative, and surgery has little role in patient management. The standard chemotherapy regimen for patients with small cell lung cancer has become either cisplatin or carboplatin with etoposide. Second-line chemotherapy regimens are moderately effective in patients previously responding to initial chemotherapy. Newer chemotherapy agents show promise, but few randomized trials have been completed in extensive disease. Physicians should be encouraged to include their patients with extensive small cell lung cancer in the evolving clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greenlee RT, Murray T, Bolden S, Wing PA: Cancer statistics, 2000. CA Cancer J Clin 1999, 49:8–31.

    Google Scholar 

  2. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973, 4:31–40.

    CAS  Google Scholar 

  3. Abrams J, Doyle LA, Aisner J: Staging, prognostic features and special considerations in small cell lung cancer. Semin Oncol 1988, 15:261–277.

    PubMed  CAS  Google Scholar 

  4. Aisner J, Alberts P, Bitran J, et al.: Role of chemotherapy is SCLC: a consensus report of the International association for the study of lung cancer workshop. Cancer Treat Rep 1983, 67:37–43.

    PubMed  CAS  Google Scholar 

  5. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 1992, 327:1434–1437.

    Article  PubMed  CAS  Google Scholar 

  6. Johnson DH: Recent developments in chemotherapy treatment of small cell lung cancer. Semin Oncol 1993, 20:315–319.

    PubMed  CAS  Google Scholar 

  7. Schabel FM, Trader MW, Caster WR, et al.: Cisdichloro-diammineplatinum: combination chemotherapy and cross resistance studies with tumors of mice. Cancer Treat Rep 1979, 63:1459–1479.

    PubMed  CAS  Google Scholar 

  8. Loeher PH, Einhorn LH, Greaco FA: Cisplatin plus etoposide in small cell lung cancer. Semin Oncol 1988, 5:2–10.

    Google Scholar 

  9. Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of Cytoxan, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991, 83:855–861.

    Article  PubMed  CAS  Google Scholar 

  10. Roth JB, Johnson DH, Einhorn LH, et al.: Randomized study of cyclophosphamide, doxorubicin and vincris-tine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10:282–286.

    PubMed  CAS  Google Scholar 

  11. Kosmidis PA, Samantas E, Fountzilas G, et al.:Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 1994, 21:23–30.

    PubMed  CAS  Google Scholar 

  12. Brahmer JR, Ettinger DS: Carboplatin in the treatment of small cell lung cancer. Oncologist 1998, 3:143–154. A review of the use of carboplatin in small cell lung cancer.

    PubMed  CAS  Google Scholar 

  13. Ihde DC, Mulshine JL, Kramer BS, et al.: Prospective randomized comparison of high dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer. J Clin Oncol 1994, 12:2022–2034.

    PubMed  CAS  Google Scholar 

  14. Elias A, Ibrajm J, Skarin AT, et al.: Dose-intensive therapy for limited stage small cell lung cancer: long term outcome. J Clin Oncol 1999, 17:1175–1184.

    PubMed  CAS  Google Scholar 

  15. Ettinger DS, Finkelstein DM, Abeloff MD, et al.:A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990, 8:230–236.

    PubMed  CAS  Google Scholar 

  16. Giaccone G, Dalesio O, McVie GJ, et al.: Maintenance chemotherapy in small cell lung cancer: long term results of a randomized trial. J Clin Oncol 1993, 11:1230–1240.

    PubMed  CAS  Google Scholar 

  17. Bleeham NM, Fayers PM, Gerling DJ, et al.: Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989, 59:584–590.

    Google Scholar 

  18. Roth BJ, Johnson DH, Einhorn LH, et al.: Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer. A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10:282–291.

    PubMed  CAS  Google Scholar 

  19. Evans WK, Feld R, Murray N, et al.: Superiority of alternating non cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 1987, 107:451–455.

    PubMed  CAS  Google Scholar 

  20. Fukuoka M, Furuse K, Saijo M, et al.: Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991, 83:855–861.

    Article  PubMed  CAS  Google Scholar 

  21. Calvert AH, Newell DR, Gumrell LA, et al.: Carboplatin dose: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748–1756.

    PubMed  CAS  Google Scholar 

  22. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31–41.

    Article  PubMed  CAS  Google Scholar 

  23. van Hazel GZ, Scott M, Eagen RT: The effect of CNS metastasis on the survival of patients with small cell cancer of the lung. Cancer 1983, 51:933–937.

    Article  PubMed  Google Scholar 

  24. Carmicheal J, Crane JM, Bunn PA, et al.: Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1988, 14:455–459. Discusses outcomes of radiation therapy for metastatic small cell lung cancer to the brain.

    Google Scholar 

  25. Chute JP, Chen T, Feigal E, et al.: Twenty years of phase III trials for patients with extensive stage small cell lung cancer: Perceptible Progress 1999, 17:1794–1801. A review of outcome of clinical trials over the past 20 years in extensive small cell lung cancer.

    CAS  Google Scholar 

  26. Kirshling RJ, Jung ST, Jett JR: A phase II trial of taxol and G-CSF in previously untreated patients with extensive small cell lung cancer (SCLC). Am Soc Clin Oncol 1994, 13:1430–1435.

    Google Scholar 

  27. Ettinger DS, Finkelstein DM, Sarma R, et al.: Phase II study of paclitaxel in patients with extensive stage small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995, 13:1430–1435.

    PubMed  CAS  Google Scholar 

  28. Hainsworth JD, Gray JR, Stoup SK, et al.: Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small cell lung cancer: comparison of sequential trials using different dose-intensities. J Clin Oncol 1997, 15:3464–3470.

    PubMed  CAS  Google Scholar 

  29. Kelly K, Pan Z, Wood ME, et al.: A phase I study of paclitaxel, etoposide and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res 1999, 5:3419–3424.

    PubMed  CAS  Google Scholar 

  30. Levitan N, McKenney J, Tahsihar H, et al.: Results of a phase I dose escalation trial of paclitaxel, etoposide and cisplatin followed by filgrastim in the treatment of patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1995, 14:379.

    Google Scholar 

  31. Glisson BS, Kurie JM, Perez-Soler R: Cisplatin, etoposide and paclitaxel in the treatment of patients with extensive small-cell lung cancer. J Clin Oncol 1999, 17:2309–2315.

    PubMed  CAS  Google Scholar 

  32. Niell HB, Miller AA, Clamon G, et al.: A phase I/II study evaluating the efficacy of carboplatin, etoposide and paclitaxel with G-CSF in extensive small cell lung cancer and stage IIIb and IV non-small cell lung cancer. Proc Am Soc Clin Oncol 1998, 17:496.

    Google Scholar 

  33. Kelly K, Bunn PA, Lovato L, et al.: Final results from Southwest Oncology Group Trial (SWOG) 9705: a phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 2000, 19:492a.

    Google Scholar 

  34. Mavroudis D, Papdakis E, Veslemes M, et al.:A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer. Proc Am Soc Clin Oncol 2000, 19:484a.

    Google Scholar 

  35. Schiller JH, Kim K, Hutson P, et al.: Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin Oncol 1996, 14:2345–2352.

    PubMed  CAS  Google Scholar 

  36. Cormier Y, Eisenhauer E, Muldal A, et al.: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Cancer Clinical Trials Group. Ann Oncol 1994, 5:2183–2285.

    Google Scholar 

  37. Masuda N, Fukuoka M, Kusunki Y, et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1992, 10:1225–1229.

    PubMed  CAS  Google Scholar 

  38. Jacobs SA, Jett JR, Belani C, et al.: Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer. Proc Am Soc Clin Oncol 1999, 18:470a.

    Google Scholar 

  39. Kudoh S, Fujiwara Y, Takada Y, et al.: Phase II study of irinotecan combination with cisplatin in patients with previously untreated small cell lung cancer: West Japan Lung Cancer Group. J Clin Oncol 1998, 16:1068–1074.

    PubMed  CAS  Google Scholar 

  40. Postumus PE, Berendsen HH, Zandwijk NV, et al.:Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. J Cancer Clin Oncol 1987, 23:1409–1411.

    Article  Google Scholar 

  41. Batist B, Carney DN, Cowan KH, et al.: Etoposide and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol 1986, 4:982–986.

    PubMed  CAS  Google Scholar 

  42. Vincent M, Evans B, Smith I: First line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988, 21:45–48.

    PubMed  CAS  Google Scholar 

  43. Shepherd FA, Evans WK, MacCormick R, et al.:Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin resistant small cell lung cancer. Cancer Treat Rep 1987, 71:941–944.

    PubMed  CAS  Google Scholar 

  44. Einhorn LH, Pennington K, McClean J: Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1990, 17:25–32.

    Google Scholar 

  45. Johnson DH, Greco FA, Strupp J, et al.: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990, 8:1613–1617.

    PubMed  CAS  Google Scholar 

  46. Lopez JA, Mann J, Gapski RT, et al.: Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 1985, 69:369–371.

    PubMed  CAS  Google Scholar 

  47. Evans WK, Osoba D, Feld R, et al.: Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small cell lung cancer. J Clin Oncol 1985, 3:65–71.

    PubMed  CAS  Google Scholar 

  48. Issell BF, Einhorn LH, Comis RL, et al.: Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treat Rep 1985, 69:127–128.

    PubMed  CAS  Google Scholar 

  49. Ardizzoni A, Hansen H, Dombernowsky P, et al.:Topotecan: a new active drug in the second-line treatment of small cell lung cancer. A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997, 15:2090–2096.

    PubMed  CAS  Google Scholar 

  50. Eckardt J, Fralia R, Palmer MC, et al.: Topotecan as second-line therapy in patients with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996, 7(suppl 5):107a.

    Google Scholar 

  51. Masuda M, Kaoru M, Shunichi N, et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1998, 18:464a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Van Vleet Cancer Center, University of Tennessee-Memphis, 3N Dunlap, 38163, Memphis, TN, USA

    Harvey B. Niell MD

Authors
  1. Harvey B. Niell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niell, H.B. Extensive stage small cell lung cancer. Curr. Treat. Options in Oncol. 2, 71–76 (2001). https://doi.org/10.1007/s11864-001-0018-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0018-4

Keywords

Search

Navigation